Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan.
Int J Clin Oncol. 2011 Aug;16(4):444-6. doi: 10.1007/s10147-010-0148-4. Epub 2010 Nov 30.
Internal jugular vein thrombosis is much less common than deep venous thrombosis of lower limbs and is generally caused by an indwelling venous catheter or otological infection. Several cases of internal jugular vein thrombosis associated with malignancy have been also reported. Bevacizumab, a monoclonal neutralizing antibody against vascular endothelial growth factor, has shown benefits in the treatment of many types of malignancy and its use is increasing. Serious adverse effects, however, are associated with the use of bevacizumab, including venous thromboembolism. In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab.
颈内静脉血栓形成比下肢深静脉血栓形成少见得多，通常由留置静脉导管或耳科感染引起。也有一些与恶性肿瘤相关的颈内静脉血栓形成的病例报告。贝伐珠单抗是一种针对血管内皮生长因子的单克隆中和抗体，已显示出对多种类型恶性肿瘤的治疗益处，其应用正在增加。然而，贝伐珠单抗的使用与严重的不良反应相关，包括静脉血栓栓塞。在本文中，我们报告了一例罕见的非小细胞肺癌病例，该病例因贝伐珠单抗引起的颈内静脉血栓形成并发肺栓塞。
